A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma

Chinese Medical Journal

Volumn 125, Issue 21, 2012, Pages 3771-3777

  Zhan, Hai lun ^a   Gao, Xin ^a   Pu, Xiao yong ^a   Li, Wei ^b   Li, Zhi jian ^b   Zhou, Xiang fu ^a   Qiu, Jian guang ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Zhongshan City People's Hospital Guangdong Province   (China)

Author keywords

Cytokine induced killer cells; Dendritic cells; Immunotherapy; Renal cell carcinoma

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DIARRHEA; DISTANT METASTASIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HYPERSENSITIVITY; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHENOTYPE; POSTOPERATIVE COMPLICATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TUMOR LYSATE PULSED DENDRITIC CELL;

ADULT; AGED; CARCINOMA, RENAL CELL; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS;

EID: 84869128048     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.21.004     Document Type: Article

References (34)

1. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urology 1999; 161: 381-386.
2. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. New Engl J Med 1998; 338: 1272-1278.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
4. Thurnher M, Radmayr C, Ramoner R, Ebner S, Böck G, Klocker H, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 1996; 68: 1-7.
5. Wang K, Gao X, Pang J, Liu X, Cai Y, Zhang Y, et al. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol Oncol 2009; 27: 26-32.
6. Zhan HL, Gao X, Qiu JG, Cai YB, Situ J, Wen XQ. Effects of dendritic cells co-cultured with CIK cells on renal carcinoma cells. Chin J Pathophysiol (Chin) 2006; 22: 1993-1998.
7. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
8. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Euro J Immunol 1997; 27: 3135-3142.
9. Baggers J, Ratzinger G, Young JW. Dendritic cells as immunologic adjuvants for the treatment of cancer. J Clin Oncol 2000; 18: 3879-3882.
10. Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol 2003; 14: 817-824.
11. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2,-7 or-12. Cancer Immunol Immunother 1998; 47: 221-226.
12. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149.
13. Dong H, Li Q, Wang J, Zhang T, Kong DL. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009; 41: 36-41.
14. Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001; 24: 502-510.
15. Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 2006; 36: 137-146.
16. Takashima K, Fujiwara H, Inada S, Atsuji K, Araki Y, Kubota T, et al. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases. Anticancer Res 2006; 26: 3327-3332.
17. Raja Gabaglia C, Diaz de Durana Y, Graham FL, Gauldie J, Sercarz EE, Braciak TA. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Res 2007; 67: 2290-2297.
18. Wang W, Epler J, Salazar LG, Riddell SR. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 2006; 66: 6826-6833.
19. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
20. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125: 257-267.
21. Svane IM, Soot ML, Buus S, Johnsen HE. Clinical application of dendritic cells in cancer vaccination therapy. Apmis 2003; 111: 818-834.
22. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 2004; 27: 265-272.
23. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995; 92: 11810-11813.
24. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696.
25. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97: 2923-2931.
26. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807.
27. Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, et al. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Intern J Cancer 2006; 119: 1377-1382.
28. Sun S, Li XM, Li XD, Yang WS. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 2005; 20: 173-180.
29. Sievers E, Albers P, Schmidt-Wolf IG, Märten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol 2004; 171: 114-119.
30. Marten A, Schottker B, Ziske C, Weineck S, Buttgereit P, Huhn D, et al. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein. J Immunother 2000; 23: 464-472.
31. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 2000; 27: 115-123.
32. Breda A, Konijeti R, Lam JS. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev Anticancer Ther 2007; 7: 847-862.
33. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
34. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56: 1743-1753.